INSERM U1107 NEURO-DOL, CHU Clermont-Ferrand, Université Clermont Auvergne, F-63000, Clermont-Ferrand, France.
Direction à la Recherche Clinique et de l'Innovation, CHU Clermont-Ferrand, F-63000, Clermont-Ferrand, France.
Support Care Cancer. 2024 Jun 13;32(7):427. doi: 10.1007/s00520-024-08627-8.
Sensory chemotherapy-induced peripheral neuropathy (CIPN) is well-recognized, but motor CIPN remains understudied. This secondary analysis focused on the long-term severity and impact of motor disorders, their relation to sensory CIPN, neuropathic pain, psychological distress, and health-related quality of life (HRQoL) after oxaliplatin-based chemotherapy in colorectal cancer (CRC) survivors.
Data from a multicenter, cross-sectional study were re-analyzed to explore motor CIPN among CRC survivors up to 5 years post-chemotherapy, with no longitudinal follow-up. Questionnaires assessed sensory and motor CIPN (QLQ-CIPN20), neuropathic pain (DN4), anxiety and depression (HADS), and HRQoL (QLQ-C30).
Among 405 CRC survivors, 31.1% had sensory CIPN as previously described. When categorizing the 405 CRC survivors based on the years since their last oxaliplatin-based chemotherapy, the motor scores derived from the QLQ-CIPN20 showed no significant difference between years (p = 0.08). Motor CIPN scores correlated with female gender, higher oxaliplatin dose intensity, sensory CIPN, and neuropathic pain. Motor CIPN also linked to decreased HRQoL and increased psychological distress.
The study underscores the detrimental impact of motor disorders on CRC survivors post-oxaliplatin-based chemotherapy. Oncologists should prioritize assessing and managing motor manifestations alongside sensory symptoms to enhance post-cancer quality of life.
NCT02970526 (2016-11-22). https://classic.
gov/ct2/show/NCT02970526?term=NCT02970526&draw=2&rank=1 .
感觉性化疗诱导的周围神经病（CIPN）已得到广泛认识，但运动性 CIPN 仍研究不足。本二次分析重点关注奥沙利铂为基础的化疗后结直肠癌（CRC）幸存者中运动障碍的长期严重程度和影响，及其与感觉性 CIPN、神经性疼痛、心理困扰和健康相关生活质量（HRQoL）的关系。
对一项多中心、横断面研究的数据进行重新分析，以探索化疗后最长 5 年内 CRC 幸存者的运动性 CIPN，无纵向随访。调查问卷评估了感觉和运动性 CIPN（QLQ-CIPN20）、神经性疼痛（DN4）、焦虑和抑郁（HADS）以及 HRQoL（QLQ-C30）。
在 405 名 CRC 幸存者中，31.1% 如前所述存在感觉性 CIPN。当根据他们最后一次奥沙利铂为基础的化疗后年份对 405 名 CRC 幸存者进行分类时，QLQ-CIPN20 得出的运动评分在各年份之间无显著差异（p=0.08）。运动性 CIPN 评分与女性性别、更高的奥沙利铂剂量强度、感觉性 CIPN 和神经性疼痛相关。运动性 CIPN 也与 HRQoL 降低和心理困扰增加有关。
该研究强调了运动障碍对奥沙利铂为基础的化疗后 CRC 幸存者的不利影响。肿瘤学家应优先评估和管理运动表现，与感觉症状一起，以提高癌症后的生活质量。
NCT02970526（2016-11-22）。[链接]。临床试验：[链接]。
